Health Care • Biotechnology: Pharmaceutical Preparations
$3.06 ▼ -0.30
(-8.93%)
MKT CAP: $16.6M • VOL: 70.1K
52W L $3 52W H $6
NEUP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $15.6M | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.1M | -$17.9M | -$22.0M |
| Operating Margin % | -7.2% | — | — |
| Net Income (GAAP) | -$369.6K | -$15.5M | -$21.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $77.2K | -$14.7M | -$14.6M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $77.2K | -$14.7M | -$14.6M |
| FCF Margin % | 0.5% | — | — |
| Return on Invested Capital (ROIC %) | -11.8% | -45.0% | — |
| Cash & Short-Term Equivalents | $22.2M | $4.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $29.7M | $13.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NEUP.